Monique Galitzky

2.3k total citations
21 papers, 1.3k citations indexed

About

Monique Galitzky is a scholar working on Neurology, Cognitive Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Monique Galitzky has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Neurology, 4 papers in Cognitive Neuroscience and 4 papers in Psychiatry and Mental health. Recurrent topics in Monique Galitzky's work include Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (10 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Monique Galitzky is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (10 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Monique Galitzky collaborates with scholars based in France, Portugal and Italy. Monique Galitzky's co-authors include Olivier Rascol, Cristina Sampaio, Claire Thalamas, François Tison, Gregor K. Wenning, Imad Ghorayeb, Carlo Colosimo, F. Yekhlef, Klaus Seppi and Werner Poewe and has published in prestigious journals such as The Lancet, Neurology and Brain Research.

In The Last Decade

Monique Galitzky

21 papers receiving 1.2k citations

Peers

Monique Galitzky
Jacob Horsager Denmark
Adjmal Nahimi Denmark
Eduardo De Pablo‐Fernández United Kingdom
Fabienne Ory France
Christine Brefel‐Courbon France
Michael Nocker Austria
Manuela Pilleri Italy
Naveed Malek United Kingdom
Mary Heumann United States
Inga Liepelt Germany
Jacob Horsager Denmark
Monique Galitzky
Citations per year, relative to Monique Galitzky Monique Galitzky (= 1×) peers Jacob Horsager

Countries citing papers authored by Monique Galitzky

Since Specialization
Citations

This map shows the geographic impact of Monique Galitzky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monique Galitzky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monique Galitzky more than expected).

Fields of papers citing papers by Monique Galitzky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monique Galitzky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monique Galitzky. The network helps show where Monique Galitzky may publish in the future.

Co-authorship network of co-authors of Monique Galitzky

This figure shows the co-authorship network connecting the top 25 collaborators of Monique Galitzky. A scholar is included among the top collaborators of Monique Galitzky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monique Galitzky. Monique Galitzky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Campo, Natalia del, Owen R. Phillips, Christine Brefel‐Courbon, et al.. (2020). Broad white matter impairment in multiple system atrophy. Human Brain Mapping. 42(2). 357–366. 20 indexed citations
2.
Meissner, Wassilios G., Anne Pavy‐Le Traon, Alexandra Foubert‐Samier, et al.. (2020). A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Movement Disorders. 35(11). 1957–1965. 56 indexed citations
3.
Nemmi, Federico, Anne Pavy‐Le Traon, Owen R. Phillips, et al.. (2019). A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. NeuroImage Clinical. 23. 101858–101858. 17 indexed citations
4.
Pasternak, Ofer, et al.. (2019). Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease. Parkinsonism & Related Disorders. 65. 146–152. 22 indexed citations
5.
Delamarre, Anna, François Tison, Qin Li, et al.. (2019). Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. Journal of Neural Transmission. 126(6). 789–793. 2 indexed citations
6.
Corvol, Jean‐Christophe, Franck Durif, Wassilios G. Meissner, et al.. (2018). Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. Parkinsonism & Related Disorders. 60. 51–56. 15 indexed citations
7.
Péran, Patrice, Gaetano Barbagallo, Federico Nemmi, et al.. (2018). MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Movement Disorders. 33(4). 600–608. 76 indexed citations
8.
Cauquil, Alexandra Séverac, et al.. (2017). Parkinson’s patients can rely on perspective cues to perceive 3D space. Brain Research. 1663. 161–165. 3 indexed citations
9.
Gourdy, Pierre, Claire Thalamas, Agnès Sommet, et al.. (2017). Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic‐euglycaemic clamp. Diabetes Obesity and Metabolism. 20(1). 157–164. 49 indexed citations
10.
Ory‐Magne, Fabienne, Jean‐Christophe Corvol, Jean‐Philippe Azulay, et al.. (2013). Withdrawing amantadine in dyskinetic patients with Parkinson disease. Neurology. 82(4). 300–307. 98 indexed citations
11.
Krismer, Florian, Klaus Seppi, François Tison, et al.. (2012). The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. Movement Disorders. 27(13). 1683–1685. 11 indexed citations
12.
13.
Rascol, Olivier, Joaquim J. Ferreira, Laurence Nègre‐Pagès, et al.. (2011). A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease. Fundamental and Clinical Pharmacology. 26(4). 557–564. 21 indexed citations
14.
Rascol, Olivier, Jean‐Philippe Azulay, Olivier Blin, et al.. (2010). Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study. Movement Disorders. 25(3). 368–376. 21 indexed citations
15.
Dellapina, Estelle, A. Gerdelat-Mas, Fabienne Ory‐Magne, et al.. (2010). Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study. Movement Disorders. 26(1). 153–157. 70 indexed citations
16.
Ferreira, Joaquim J., Monique Galitzky, Claire Thalamas, et al.. (2006). Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers. European Journal of Neurology. 13(3). 209–214. 60 indexed citations
17.
Wenning, Gregor K., François Tison, Klaus Seppi, et al.. (2004). Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Movement Disorders. 19(12). 1391–1402. 433 indexed citations
18.
Durif, Franck, B. Debilly, Monique Galitzky, et al.. (2004). Clozapine improves dyskinesias in Parkinson disease. Neurology. 62(3). 381–388. 166 indexed citations
19.
Brefel‐Courbon, Christine, Claire Thalamas, Monique Galitzky, et al.. (2003). Clinical and economic analysis of spa therapy in Parkinson's disease. Movement Disorders. 18(5). 578–584. 29 indexed citations
20.
Ferreira, Joaquim J., Monique Galitzky, Claire Thalamas, et al.. (2002). Effect of ropinirole on sleep onset: A randomized, placebo-controlled study in healthy volunteers. Neurology. 58(3). 460–462. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Horsager Breakdown of academic impact, for papers by Adjmal Nahimi Breakdown of academic impact, for papers by Eduardo De Pablo‐Fernández Breakdown of academic impact, for papers by Fabienne Ory Breakdown of academic impact, for papers by Christine Brefel‐Courbon Breakdown of academic impact, for papers by Michael Nocker Breakdown of academic impact, for papers by Manuela Pilleri Breakdown of academic impact, for papers by Naveed Malek Breakdown of academic impact, for papers by Mary Heumann Breakdown of academic impact, for papers by Inga Liepelt
Rankless by CCL
2026